Lots of interesting abstracts and cases were submitted for TCTAP 2024. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-005
Proper Sizing Takes into Consideration of Annular and Supra-Annular Planes and Calcium Distribution Can Improve Outcomes of Transcatheter Aortic Valve Replacement With Both Balloon-Expandable and Self-Expanding Valves
By Wei-Hsian Yin, Yung-Tsai Lee, Kuo Chen Lee, Tien Ping Tsao, Jeng Wei
Presenter
Wei-Hsian Yin
Authors
Wei-Hsian Yin1, Yung-Tsai Lee1, Kuo Chen Lee1, Tien Ping Tsao1, Jeng Wei1
Affiliation
Cheng Hsin General Hospital, Taiwan1
View Study Report
TCTAP A-005
Bicuspid AV
Proper Sizing Takes into Consideration of Annular and Supra-Annular Planes and Calcium Distribution Can Improve Outcomes of Transcatheter Aortic Valve Replacement With Both Balloon-Expandable and Self-Expanding Valves
Wei-Hsian Yin1, Yung-Tsai Lee1, Kuo Chen Lee1, Tien Ping Tsao1, Jeng Wei1
Cheng Hsin General Hospital, Taiwan1
Background
Comprehensive computed tomography (CT)-based sizing combines annular and supra-annular planes and takes into consideration calcium distribution (the Wei’s sizing method) has been used at our institution since 2016 for transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis (AS). We sought to evaluate the performances and 30-day clinical outcomes of transcatheter heart valves (THVs) in the treatment of bicuspid AS based on the Wei’s method.
Methods
We retrospectively evaluated consecutive patients, who underwent TAVR with balloon-expandable Sapien 3 valves (Edwards Lifesciences, Irvine, CA) or self-expanding Evolut R/PRO valves (Medtronic, Minneapolis, MN) for the treatment of severe bicuspid AS from 2017 to 2021. The primary end-point was device success rate and valve performance at 30 days.
Results
A total of 75 patients (n=43 treated with Sapien3 and n=32treated with Evolut R/PRO) were included. The mean age was 71±12years and themean Society of Thoracic Surgeons Predicted Risk of Mortality was 4 .4±3.5%.Device success was similar between Sapien 3 and Evolut R/PRO (93% vs.91%;P=0.999). In both groups, no patients experienced annular rupture, and nodifferences in the rate of permanent pacemaker implants (5% vs.9%; P=0.731)were observed. The 30-day echocardio graphic follow-up demonstrated asimilar effective orifice area (Sapien 3 vs. EvolutR/PRO = 1.9±0.3cm2 vs. 1.9±0.4cm2, P=0.705)and rate of moderate-to-severe paravalvular aortic regurgitation (PAR) (Sapien 3vs. Evolut R/PRO = 5% vs. 6%, P=1.0).No evidence of valve thrombosis orclinically relevant events was noted in both valves.
Conclusion
Ourstudy confirms that with proper sizing takes into consideration of both annularand supra-annular planes can yield good results of TAVR with both Sapien 3 andEvolut R/PRO implantation in bicuspid aortic valve anatomy.